Combining GLS inhibitors with targeted therapy can suppress glutamine production and asparagine synthesis via their respective metabolic pathways, restoring tumor cell sensitivity to ASNase and significantly reducing asparagine levels, thereby increasing therapeutic efficacy (221). This evidence concerns the gene GLS and neoplasm.